(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 220 685 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
31.03.2004 Bulletin 2004/14

(21) Application number: **00967197.5**

(22) Date of filing: **29.09.2000**

(51) Int Cl.[7]: **A61K 38/48**, A61K 47/12, A61K 9/19, A61P 7/02

(86) International application number:
PCT/US2000/027022

(87) International publication number:
WO 2001/024817 (12.04.2001 Gazette 2001/15)

(54) PHARMACEUTICAL COMPOSITIONS OF FIBRINOLYTIC AGENT

PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS FIBRINOLYTISCHEM MITTEL

COMPOSITIONS PHARMACEUTIQUES D'AGENT FIBRINOLYTIQUE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **01.10.1999 US 411335**

(43) Date of publication of application:
10.07.2002 Bulletin 2002/28

(73) Proprietor: **Amgen Inc.**
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
- **KENDRICK, Brent, S.**
Louisville, CO 80027 (US)
- **PETERSON, Brian**
Simi Valley, CA 93065 (US)

(74) Representative: **Richardson, Kate et al**
Forrester & Boehmert,
Pettenkoferstrasse 20-22
80336 München (DE)

(56) References cited:
EP-A- 0 624 642 **EP-A- 0 689 843**
US-A- 4 083 961

- **POTEMPA J ET AL: "STABILIZATION VS. DEGRADATION OF STAPHYLOCOCCUS-AUREUS METALLOPROTEINASE" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 993, no. 2-3, 1989, pages 301-304, XP000992761 ISSN: 0006-3002**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 220 685 B1

Description

Field of the Invention

[0001] The present invention relates to novel pharmaceutical compositions of a fibrinolytic agent. More specifically, the present invention relates to frozen liquid and lyophilized compositions of fibrolase and, separately, of "novel acting thrombolytic" (NAT), as well as methods for the production and use thereof.

Background of the Invention

[0002] In general, polypeptides are marginally stable in the aqueous state and undergo chemical and physical degradation resulting in a loss of biological activity during processing and storage. Another problem encountered in aqueous solution in particular is hydrolysis, such as deamidation and peptide bond cleavage. These effects represent a serious problem for therapeutically active polypeptides which are intended to be administered to humans within a defined dosage range based on biological activity.

[0003] To reduce the degradation of polypeptides, water-based pharmaceutical compositions are generally kept refrigerated or frozen until ready for use. As an alternative, the process of freeze-drying is often employed to stabilize polypeptides for long-term storage, particularly when the polypeptide is relatively unstable in liquid compositions. A lyophilization cycle is usually composed of three steps: freezing, primary drying, and secondary drying; Williams and Polli, Journal of Parenteral Science and Technology, Volume 38, Number 2, pages 48-59 (1984).
In the freezing step, the solution is cooled until it is adequately frozen. Bulk water in the solution forms ice at this stage. The ice sublimes in the primary drying stage, which is conducted by reducing chamber pressure below the vapor pressure of the ice, using a vacuum. Finally, sorbed or bound water is removed at the secondary drying stage under reduced chamber pressure and an elevated shelf temperature. The process produces a material known as a lyophilized cake. Thereafter the cake can be reconstituted prior to use.

[0004] The standard reconstitution practice for lyophilized material is to add back a volume of pure water (typically equivalent to the volume removed during lyophilization), although dilute solutions of antibacterial agents are sometimes used in the production of pharmaceuticals for parenteral administration; Chen, Drug Development and Industrial Pharmacy, Volume 18, Numbers 11 and 12, pages 1311-1354 (1992).

[0005] Lyophilization is considered one of the best ways to remove excess water from polypeptide solutions. The freeze-drying process may yield products that are stable and amenable to handling for long-term storage. Lyophilized products can be stored at room temperature and are therefore easier to handle and distribute to a wider geographic market, such as foreign markets where refrigeration may not be available.

[0006] Excipients have been noted in some cases to act as stabilizers for freeze-dried products; Carpenter et al., Developments in Biological Standardization, Volume 74, pages 225-239 (1991). For example, known excipients include polyols (including mannitol, sorbitol and glycerol); sugars (including glucose and sucrose); and amino acids (including alanine, glycine and glutamic acid).

[0007] In addition, polyols and sugars are also often used to protect polypeptides from freezing and drying-induced damage and to enhance the stability during storage in the dried state. In general, sugars, in particular disaccharides, are effective in both the freeze-drying process and during storage. Other classes of molecules, including mono- and disaccharides and polymers such as PVP, have also been reported as stabilizers of lyophilized products.

Summary of the Invention

[0008] The present invention relates to stable pharmaceutical compositions of fibrolase and "novel acting thrombolytic" (NAT), some of which are liquid compositions suitable for storage in the frozen state, and others of which are suitable for lyophilization.

[0009] Because of the fibrinolytic properties of fibrolase and NAT, the compositions of this invention are useful to lyse blood clots in vivo and may be administered therapeutically for such a purpose.

[0010] For purposes of this invention, the term "NAT" refers to the metalloproteinase having fibrinolytic activity which is characterized by SEQ ID NO: 1. The NAT polypeptide is encoded by the cDNA molecule of SEQ ID NO: 2, although any DNA molecule of variant sequence encoding the same polypeptide may be used for expression and manufacture in accordance with methods which are referred to hereinbelow.

[0011] Fibrolase is a known metalloproteinase which has been described in the scientific and patent literature; see Randolph et al., Protein Science, Cambridge University Press (1992), pages 590-600, and European patent Application No. 0 323 722 (Valenzuela et al.), published July 12, 1989. Typically, the fibrolase employed in the compositions of this invention will be of SEQ ID NO: 3, which is encoded by the cDNA molecule of SEQ ID NO: 4 (or variants thereof encoding the same amino acid sequence).

[0012] Fibrolase and NAT are to be distinguished from other therapeutic agents for the treatment of blood clots *in vivo*, such as urokinase, streptokinase and tPA which are plasminogen activators. Unlike these other agents, fibrolase and NAT act directly on the clot to degrade both fibrin and fibrinogen.

[0013] The pharmaceutical compositions of this invention may contain, in addition to a therapeutically effective amount of fibrolase or NAT, a zinc stabilizer and, optionally, a bulking agent with or without other excipients in a pharmaceutically-acceptable buffer which, in combination, provide a stable, frozen or lyophilized product that can be stored for an extended period of time.

[0014] In one of its aspects, the present invention provides a freezable liquid medicinal composition comprising fibrolase or NAT, a water soluble zinc salt, a citric acid buffer, optionally an additional stabilizer selected from the group consisting of water soluble calcium salts, and optionally a bulking agent (for example, mannitol). A surfactant, such as Tween 80 (BASF, Gurnee, Illinois), may also be added to increase freeze-thaw stability. Tris buffer (Sigma, St. Louis, Missouri) or another buffer with a buffer capacity above pH 7.0 may be added to stabilize the pH at or above pH 7.4.

[0015] In another aspect of the present invention, the pharmaceutical composition can be a lyophilizable or lyophilized pharmaceutical composition comprising fibrolase or NAT, a zinc stabilizer (e.g., water soluble zinc salt), and a citric acid buffer, with or without other excipients (e.g., bulking agent such as mannitol, glycine, or the like). The lyophilized composition may also contain a disaccharide sugar, such as sucrose or trehalose, as a lyoprotectant. A surfactant, such as Tween 80, may be added to protect against lyophilization stresses on the metalloproteinase (fibrolase or NAT). The pH will ideally be maintained at pH 8.0 ± 0.5, using a suitable buffer with a pK_a in this range (for example, Tris).

[0016] The invention also relates to a method for preparing a lyophilized composition, comprising the steps of (i) mixing fibrolase or NAT with a buffer and a water soluble zinc salt, as well as any desired optional ingredients, and (ii) lyophilizing this mixture.

[0017] In addition, the invention relates to a kit for preparing an aqueous pharmaceutical composition, comprising a first container having the aforementioned lyophilized composition and a second container having a physiologically acceptable solvent therefor.

[0018] Still another aspect of this invention relates to a method comprising the steps of reconstituting the lyophilized composition and

administering the reconstituted composition to a patient in need of blood clot lysis.

[0019] According to the present invention there is provided a pharmaceutical composition comprising a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), a zinc stabilizer and, optionally, a bulking agent, in a pharmaceutically-acceptable buffer.

[0020] The present invention also provides a method for preparing a lyophilized composition, comprising the steps of:

(a) forming a mixture of a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), a zinc salt, a bulking agent, a stabilizing disaccharide and a surfactant in a buffer, and

(b) lyophilizing the mixture from step (a).

[0021] In addition, the present invention provides a kit for preparing an aqueous pharmaceutical composition comprising a first container having a lyophilized composition of a zinc stabilizer and a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), and a second container having a physiologically acceptable solvent for the lyophilized composition.

[0022] Also provided are compositions of the present invention for use in blood clot lysis treatment and use of compositions of the invention for the manufacture of a medicament for us in blood clot lysis treatment.

[0023] The present invention additionally provides an *in vitro* method of lysing a fibrin clot, the method consisting of contacting the fibrin clot with a metalloproteinase fibrinolytic agent selected from the group comprising fibrolase and novel acting thrombolytic (NAT), a zinc stabiliser and, optionally, a bulking agent, in a pharmaceutically-acceptable buffer.

Detailed Description of the Invention

[0024] A variety of host-vector systems may be utilized to express the coding sequence for fibrolase or NAT polypeptide in accordance with standard methods for recombinant expression which are well known to those skilled in the art, and thereby obtain the fibrinolytically active polypeptide for the compositions. Such systems include, but are not limited to, eukaryotic cell systems such as mammalian cell systems infected with virus (for example, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (for example, baculovirus); microorganisms such as yeast containing yeast vectors; or prokaryotic cell systems such as bacteria (e.g., E. coli) transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. The expression elements of these vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

[0025] Preferably, a yeast expression system (e.g., *Pichia pastoris*) is employed for recombinant expression because of its greater efficiency. A detailed description of such a system may be found in United States Patent No. 4,855,231 (Stroman et al.), United States Patent No. 4,812,405 (Lair et al.), United States Patent No. 4,818,700 (Cregg et al.), United States Patent No. 4,885,242 (Cregg), and United States Patent No. 4,837,148 (Cregg), the disclosures of which are hereby incorporated by reference. Expression of fibrolase in such a system will typically involve a DNA molecule of SEQ ID NO: 5, which encodes "prepro" sequence (nucleotides 1-783) in addition to the "mature" polypeptide (nucleotides 784-1392). Expression of NAT in such a system will typically involve a DNA molecule of SEQ ID NO: 6, which encodes "prepro" sequence (nucleotides 1-783) in addition to the "mature" polypeptide (nucleotides 784-1386).

[0026] Further details regarding NAT and methods for its preparation may be found in commonly assigned copending patent application publ. no: WO 0125445, filed concurrently herewith.

[0027] Once the polypeptide (fibrolase or NAT) has been prepared, purified, and then assayed for activity (using procedures for fibrinolytic agents known to those skilled in the art), it may be formulated into pharmaceutical compositions in accordance with this invention.

[0028] In the present compositions (whether frozen or lyophilized), a stabilizer (which can also be referred to as a "glass-forming additive") is added to prevent or reduce precipitation and chemical degradation of fibrolase or NAT, whichever the case may be. A hazy or turbid solution at room temperature indicates that the polypeptide has precipitated. The term "stabilizer" means an excipient capable of preventing aggregation or other physical degradation, as well as chemical degradation (for example, autolysis, deamidation, oxidation, etc.) of fibrolase or NAT in an aqueous medium.

[0029] It has been found that the incorporation of a zinc stabilizer, and more specifically a water soluble zinc salt, increases the stability of the metalloproteinase (fibrolase or NAT) in each type of composition, as compared to formulations in which inorganic or other types of organic compounds are used to prevent aggregation and/or polypeptide decomposition. Specifically, zinc concentrations above 0.01 millimolar (mM) will stabilize the metalloproteinase, with the proviso that zinc concentrations above 1 mM significantly limit the solubility of fibrolase or NAT. Thus, a range from about 0.01 mM to about 1 mM is advised. Examples of suitable zinc salts are zinc acetate, zinc sulfate and zinc chloride.

[0030] Frozen liquid compositions in accordance with this invention, in particular, may optionally (but not necessarily) also include a water soluble calcium salt as an additional stabilizer. Examples are calcium acetate, calcium sulfate or calcium chloride, which are preferably present in a concentration from about 0.001 to about 0.02 mM, and more preferably at a concentration of about 0.01 ± 0.002 mM.

[0031] If desired, other stabilizers that are conventionally employed in pharmaceutical compositions, such sucrose, trehalose or glycine, may be used in addition to the above mentioned. Typically, such stabilizers will be added in minor amounts ranging from, for example, about 0.1% to about 0.5% (w/v). Surfactant stabilizers, such as Tween 20 or Tween 80 (BASF), may also be added in conventional amounts.

[0032] If desired, the frozen liquid and lyophilized compositions can also include a bulking/osmolarity regulating agent. Preferably, mannitol is incorporated in a concentration of about 2% to about 8% weight by volume (w/v), and usually at a concentration of about 5% (w/v).

[0033] The choice of a pharmaceutically-acceptable buffer and pH has also been found to affect the stability of the present compositions. Fibrolase or NAT is most stable above a neutral pH (7.0). Significant precipitation of either metalloproteinase occurs at a pH below 7.0 when the frozen composition is thawed or the lyophilized composition is reconstituted. The buffer system present in the compositions is selected to be physiologically compatible and to maintain a desired pH in the reconstituted solution as well as in the solution before lyophilization. Preferably, the buffers have a pH buffering capacity in the range of from about pH 7.0 to about pH 8.5.

[0034] Specifically, citric acid buffers (i.e., citric acid or a citric acid salt) are preferably incorporated in a concentration of about 20 mM to about 110 mM, and most preferably at about 100 mM in the frozen liquid composition and about 20 mM in the lyophilized composition. Citric acid salts are used as both buffering agents and stabilizing agents in the compositions of this invention. Whether an acid form itself or a salt thereof is used, the citric acid buffer will be chosen to adjust the pH of the composition to a value within the desired range as indicated above (in the case of the lyophilized composition, after reconstitution). Additional buffering agents, such as Tris, may be added in suitably effective amounts to maintain an adequate buffering capacity above pH 7.0.

[0035] A preferred liquid composition to be frozen will contain, in addition to solubilized fibrolase or NAT, zinc acetate in a concentration of about 0.08 mM to about 0.12 mM, calcium acetate in a concentration of about 0.008 mM to about 0.012 mM, and citric acid (or sodium citrate) in a concentration of about 95 mM to about 105 mM, at about pH 7.4. Another preferred liquid composition will contain fibrolase or NAT, zinc acetate in a concentration of about 0.08 mM to about 0.12 mM, citric acid (or sodium citrate) in a concentration of about 18 mM to about 22 mM, Tris in a concentration of about 0.02 mM to about 0.06 mM, mannitol in a concentration of about 3% to about 6% (w/v), and Tween 80 in a concentration of about 0.008% to about 0.012% (w/v), at a pH of about 8.0.

[0036] A preferred lyophilizable composition for will contain, in addition to fibrolase or NAT, zinc sulfate in a concentration of about 0.08 mM to about 0.12 mM, citric acid (or sodium citrate) in a concentration of about 18 mM to about

22 mM, Tris in a concentration of about 3 mM to about 6 mM, mannitol in a concentration of about 3% to about 6% (w/v), and Tween 80 in a concentration of about 0.008% to about 0.012% (w/v), at a pH of about 8.0.

[0037] For all compositions in accordance with this invention, fibrolase or NAT is present in a concentration of about 0.1 mg/ml to about 50 mg/ml, preferably, with a concentration of about 5 mg/ml to about 40 mg/ml being more preferred, and a concentration of about 10 mg/ml to about 15 mg/ml being the most preferred.

[0038] The relative proportions of the excipients in these compositions will depend on several factors. For example, the amount of the metalloproteinase and bulking agent (e.g., mannitol) has an effect on the amount of zinc (and calcium, if present) needed to stabilize the composition. The amount of stabilizer used in the compositions will depend on the amount needed to maintain the structural integrity of fibrolase or NAT during lyophilization or other processing or upon storage.

[0039] Still other excipients known in the art can also be included in the composition, provided they are physiologically compatible and are in no way detrimental to fibrolase or NAT. For example, the composition may contain minor amounts of additives, such as preservatives, tonicity-adjusting agents, antioxidants, or other polymers (for example, viscosity adjusting agents or extenders). Those skilled in the art can readily determine appropriate reagents that would be pharmaceutically useful, based on knowledge of and experience with other pharmaceutical compositions. See, for example, Remington's Pharmaceutical Sciences (latest edition), Mack Publishing Company, Easton, PA.

[0040] The compositions are expected to be stable for at least two years at -30°C for the frozen composition, and two years at 2°C to 8°C for the lyophilized composition. This long-term stability is beneficial for extending the shelf life of the pharmaceutical product and for long distance shipments.

[0041] In another aspect, the present invention also provides a method for preparing a lyophilized composition comprising the steps of:

(a) adjusting the pH of a mixture containing the composition ingredients without fibrolase or NAT to between pH 7.6 and pH 8.2,

(b) buffer exchanging a fibrolase or NAT containing solution into the composition solution of step (a) and then adding an effective amount of surfactant, and

(c) lyophilizing the mixture of step (b).

[0042] Fibrolase or NAT and effective amounts of the excipients are admixed under conditions effective to reduce aggregation of the dried fibrolase or NAT polypeptide upon reconstitution with the reconstitution medium, e.g., a solvent which is compatible with the selected administration route and does not negatively interfere with the metalloproteinase, such as sterile water, physiological saline solution, glucose solution or other aqueous solvents (e.g., alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or mixtures thereof) and, optionally, other components such as antibacterial agents.

[0043] The excipients may be admixed with the metalloproteinase at a suitable time before lyophilization. The time taken to mix the excipients and metalloproteinase should be for a sufficient period to prepare a suitable admixture; preferably, mixing will be carried out from about one to about thirty minutes.

[0044] Thereafter, the formulated metalloproteinase may be lyophilized, stored and reconstituted using standard methods; see Pikal, supra. The specific conditions under which fibrolase or NAT is freeze-dried and reconstituted are not particularly critical, provided that the conditions selected do not degrade the metalloproteinase and not be deleterious to the stabilizer. A preferred lyophilization cycle comprises freezing the composition at -40°C, annealing the frozen sample at -12°C, and conducting the primary drying at-30°C to -35°C for twenty to fifty hours and secondary drying at 20°C for twenty to forty hours. Generally, the reconstituted composition will be used soon after reconstitution.

[0045] Both NAT and fibrolase are best delivered locally to the site of the clot for most effective treatment. Like fibrolase, NAT is covalently bound by α_2 macroglobulin in the general circulation. While complexed with α_2 macroglobulin, neither fibrolase nor NAT can access the target substrate (i.e., fibrin or fibrinogen) and are largely ineffective unless and until the maximum innate levels of α_2 macroglobulin are exceeded. Thus, it is preferred that the compositions of this invention be administered directly to the blood clot via intraarterial or intravenous catheterization.

Description of Specific Embodiments

[0046] The following examples further illustrate of the present invention.

[0047] The recombinant NAT (SEQ ID NO: 1) used in Examples 1-3 was produced by expression in *P. pastoris* Details regarding a suitable expression system and method may be found in the Stroman et al., Lair et al., Cregg et al. and Cregg patents referred to above. All chemicals were either analytical or USP grade.

Example 1

Preparation of Frozen Liquid Composition

[0048] An aqueous solution containing 100 mM of citric acid, 0.01 mM of calcium acetate and 0.1 mM of zinc sulfate is prepared by admixture of the ingredients, with the pH adjusted to 7.4. An NAT-containing solution is buffer exchanged into the solution by dialysis (alternatively, ultrafiltration can be used). The resulting NAT solution is concentrated to 10 mg/ml and stored frozen at a temperature of -30°C until ready for use.

Example 2

Preparation of Lyophilized Composition

[0049] Preparation of lyophilizable composition. An aqueous solution containing 5 mM of Tris, 20 mM of citric acid, 5% (w/v) of mannitol, 0.5% (w/v) of sucrose and 0.1 mM of zinc sulfate was prepared by admixture of the ingredients, with the pH adjusted to 8.0. A NAT containing solution was buffer exchanged into the composition solution by dialysis (ultrafiltration can be used instead). The resulting NAT solution was concentrated to 10 to 12 mg/ml. Tween 80 was added to a final concentration of 0.01% (w/v). The solution was stored at a temperature of 2-8°C until ready for lyophilization.

Freeze-drying cycle for lyophilized product. The above-prepared composition was first frozen at a temperature of -40°C in the lyophilizer. The annealing temperature was set at -12°C; the primary drying temperature was set at -30°C; and the secondary drying temperature was set at 20°C. The resulting freeze-dried cake showed good morphology and contained less than 3% water, as detected by the Karl Fischer titration method; see Fischer, *Angew Chemie*, Volume 48, page 394 (1935). After the freeze-drying process was finished, the lyophilized cake was put into vials and rubber stoppers were sealed completely under vacuum by pressing down the upper metal shelves in the lyophilizer. The vials were then crimped with 13-mm flip-off aluminum seals and placed in incubators set at different temperatures.

Example 3

Analyses of Reconstituted Lyophilized Samples

[0050] Sample time points analysis. Sample vials were withdrawn from incubators at predetermined time intervals for the time points analysis. The lyophilized sample cake was first reconstituted by 0.9 ml of sterile water, i.e., "water-for-injection" (McGaw Inc., Irvine, CA). Clarity of the reconstituted sample solutions was visually examined. The filtered solution was analyzed by HPLC, UV-Vis spectroscopy and enzyme activity in order to quantify the remaining soluble NAT in these lyophilized samples.

[0051] Based on the above analyses, greater than 90% of NAT was recovered after reconstitution of the lyophilized product.

[0052] UV/Vis absorbence. 150-200 µl of NAT solution was loaded into a quartz glass suprasil 1-cm path length ultramicrocell. UV/Vis absorbence was measured on an HP 8452A diode-array spectrophotometer (Hewlett-Packard Co., Wilmington, DE). NAT concentrations were determined using $A^{0.1\%} = 1.05$ at 280 nm, based on calculation from the amino acid composition; for reference, see Edelhoch, Biochemistry, Volume 6, pages 1948-1954 (1967). After rehydration of the lyophilized product, no detectable turbidity was observed when measuring the absorbence at 350 nanometers (nm).

[0053] High performance liquid chromatography. HPLC analyses of NAT samples were performed using an HP 1050 liquid chromatography system equipped with an HP 3D Chemstation for data acquisition (Hewlett-Packard Co.). NAT species were detected by absorbence at 280 nm and 214 nm using an HP diode-array detector.

[0054] For reversed-phase HPLC (RP-HPLC), samples were injected onto a Zorbax 300SB -C8 column (4.6 X 250 mm) (Hewlett-Packard Co.) in a mobile phase consisting of 51.5% buffer A (2% isopropanol, 0.1% TFA) and 48.5% buffer B (90% acetonitrile, 2% isopropanol, 0.1% TFA) at a flow rate of 0.6 ml/min. Buffer B was held for six minutes and then ramped up to 51% over twenty minutes. This concentration was held for one minute, followed by an eight-minute ramp and five-minute hold at 90%. Finally, buffer B was ramped back to 48.5% over a period of three minutes. Recovery of NAT after lyophilization as detected by this method was greater than 92%.

[0055] For ion-exchange HPLC (IEX-HPLC), samples were injected onto a Tosohaas DEAE-5PW column (7.5 X 75 mm) (Tosohaas, Montgomeryville, Alabama) in a mobile phase consisting of 90% buffer A (20 mM Tris, pH 8.5) and 10% buffer B (20 mM Tris, 250 mM NaCl, pH 8.5) at a flow rate of 0.5 ml/min. Then a gradient was applied, increasing from 10% buffer B to 75% buffer B in 20 minutes, then from 75% B to 90% buffer B in one minute. Buffer B was then held for five minutes, followed by a ramp to 10% buffer B in four minutes. Recovery of NAT after lyophilization as

detected by this method was greater than 90%.

[0056] For size-exclusion HPLC (SEC-HPLC), samples were loaded into a Tosohaas G-2000SWXLcolumn (300 x 7.8 mm). Isocratic elution was applied at a flow rate of 0.8 ml/min using a buffer containing 15 mM sodium phosphate, pH 7.0, and 0.140 M sodium chloride. Recovery of NAT after lyophilization as detected by this method was greater than 95%.

[0057] Bioassay. Samples were screened for activity against fibrin clots. Small aliquots of a serial dilution of NAT ranging from 0.01 to 1.0 mg/ml were loaded onto preformed fibrin clots in 96-well plates. The samples were incubated for eighteen hours, and clot lysis was quantitated by absorbence at 500 nm. A plot of absorbence vs. NAT concentration for various formulations were compared to a prepared NAT standard for relative activity. There was no measurable difference in the fibrinolytic activity of the NAT after lyophilization, relative to the control (non-lyophilized) sample.

[0058] Similar test results are obtained with the frozen liquid composition as well, after the latter is thawed at 4°C and tested using these same protocols.

[0059] The foregoing invention has been described in some detail for purposes of clarity and understanding. It will also be obvious that various other combinations in form and detail can be made without departing from the scope of the invention as defined in the appended claims.

Example 4

[0060] The procedures of Examples 1 and 2 are repeated with recombinant fibrolase in place of NAT to produce similar frozen liquid and lyohilized pharmaceutical compositions.

SEQUENCE LISTING

[0061]

<110> Kendrick, Brent S.
Peterson, Brian A.
<120> PHARMACEUTICAL COMPOSITIONS OF FIBRINOLYTIC AGENT
<130> A-578
<140> N/A
<141> 1999-10-01
<160> 6
<170> PatentIn Ver. 2.0
<210> 1
<211> 201
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: NAT (analog of fibrolase of Agkistrodon Contortrix)
<400> 1

```
Ser Phe Pro Gln Arg Tyr Val Gln Leu Val Ile Val Ala Asp His Arg
 1               5                  10                  15

Met Asn Thr Lys Tyr Asn Gly Asp Ser Asp Lys Ile Arg Gln Trp Val
            20                  25                  30

His Gln Ile Val Asn Thr Ile Asn Glu Ile Tyr Arg Pro Leu Asn Ile
        35                  40                  45

Gln Phe Thr Leu Val Gly Leu Glu Ile Trp Ser Asn Gln Asp Leu Ile
    50                  55                  60

Thr Val Thr Ser Val Ser His Asp Thr Leu Ala Ser Phe Gly Asn Trp
65                  70                  75                  80

Arg Glu Thr Asp Leu Leu Arg Arg Gln Arg His Asp Asn Ala Gln Leu
                85                  90                  95

Leu Thr Ala Ile Asp Phe Asp Gly Asp Thr Val Gly Leu Ala Tyr Val
            100                 105                 110

Gly Gly Met Cys Gln Leu Lys His Ser Thr Gly Val Ile Gln Asp His
        115                 120                 125

Ser Ala Ile Asn Leu Leu Val Ala Leu Thr Met Ala His Glu Leu Gly
    130                 135                 140

His Asn Leu Gly Met Asn His Asp Gly Asn Gln Cys His Cys Gly Ala
145                 150                 155                 160

Asn Ser Cys Val Met Ala Ala Met Leu Ser Asp Gln Pro Ser Lys Leu
                165                 170                 175

Phe Ser Asp Cys Ser Lys Lys Asp Tyr Gln Thr Phe Leu Thr Val Asn
            180                 185                 190

Asn Pro Gln Cys Ile Leu Asn Lys Pro
        195                 200
```

<210> 2
<211> 603
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Encodes NAT (analog of fibrolase)
<400> 2

```
tctttcccac aaagatacgt acagctggtt atcgttgctg accaccgtat gaacactaaa 60
tacaacggtg actctgacaa aatccgtcaa tgggtgcacc aaatcgtcaa caccattaac 120
gaaatctaca gaccactgaa catccaattc actttggttg gtttggaaat ctggtccaac 180
caagatttga tcaccgttac ttctgtatcc cacgacactc tggcatcctt cggtaactgg 240
cgtgaaaccg acctgctgcg tcgccaacgt catgataacg ctcaactgct gaccgctatc 300
gacttcgacg gtgatactgt tggtctggct tacgttggtg gcatgtgtca actgaaacat 360
tctactggtg ttatccagga ccactccgct attaacctgc tggttgctct gaccatggca 420
cacgaactgg gtcataacct gggtatgaac cacgatggca accagtgtca ctgcggtgca 480
aactcctgtg ttatggctgc tatgctgtcc gatcaaccat ccaaactgtt ctccgactgc 540
tctaagaaag actaccagac cttcctgacc gttaacaacc cgcagtgtat cctgaacaaa 600
ccg                                                               603
```

<210> 3
<211> 203
<212> PRT
<213> Agkistrodon contortrix
<220>
<223> Native fibrolase of Agkistrodon Contortrix
<400> 3

```
Gln Gln Arg Phe Pro Gln Arg Tyr Val Gln Leu Val Ile Val Ala Asp
 1               5                  10                  15

His Arg Met Asn Thr Lys Tyr Asn Gly Asp Ser Asp Lys Ile Arg Gln
            20                  25                  30

Trp Val His Gln Ile Val Asn Thr Ile Asn Glu Ile Tyr Arg Pro Leu
        35                  40                  45

Asn Ile Gln Phe Thr Leu Val Gly Leu Glu Ile Trp Ser Asn Gln Asp
    50                  55                  60

Leu Ile Thr Val Thr Ser Val Ser His Asp Thr Leu Ala Ser Phe Gly
65                  70                  75                  80
```

```
Asn Trp Arg Glu Thr Asp Leu Leu Arg Arg Gln Arg His Asp Asn Ala
                  85                  90                  95

Gln Leu Leu Thr Ala Ile Asp Phe Asp Gly Asp Thr Val Gly Leu Ala
             100                 105                 110

Tyr Val Gly Gly Met Cys Gln Leu Lys His Ser Thr Gly Val Ile Gln
         115                 120                 125

Asp His Ser Ala Ile Asn Leu Leu Val Ala Leu Thr Met Ala His Glu
     130                 135                 140

Leu Gly His Asn Leu Gly Met Asn His Asp Gly Asn Gln Cys His Cys
145                 150                 155                 160

Gly Ala Asn Ser Cys Val Met Ala Ala Met Leu Ser Asp Gln Pro Ser
                 165                 170                 175

Lys Leu Phe Ser Asp Cys Ser Lys Lys Asp Tyr Gln Thr Phe Leu Thr
             180                 185                 190

Val Asn Asn Pro Gln Cys Ile Leu Asn Lys Pro
         195                 200
```

<210> 4
<211> 609
<212> DNA
<213> Agkistrodon contortrix
<220>
<223> Encodes native fibrolase of Agkistrodon Contortrix
<400> 4

```
caacaaagat tcccacaaag atacgtacag ctggttatcg ttgctgacca ccgtatgaac 60
actaaataca acggtgactc tgacaaaatc cgtcaatggg tgcaccaaat cgtcaacacc 120
attaacgaaa tctacagacc actgaacatc caattcactt tggttggttt ggaaatctgg 180
tccaaccaag atttgatcac cgttacttct gtatcccacg acactctggc atccttcggt 240
aactggcgtg aaaccgacct gctgcgtcgc caacgtcatg ataacgctca actgctgacc 300
gctatcgact tcgacggtga tactgttggt ctggcttacg ttggtggcat gtgtcaactg 360
aaacattcta ctggtgttat ccaggaccac tccgctatta acctgctggt tgctctgacc 420
atggcacacg aactgggtca taacctgggt atgaaccacg atggcaacca gtgtcactgc 480
ggtgcaaact cctgtgttat ggctgctatg ctgtccgatc aaccatccaa actgttctcc 540
gactgctcta agaaagacta ccagaccttc ctgaccgtta acaacccgca gtgtatcctg 600
aacaaaccg                                                        609
```

<210> 5
<211> 1392
<212> DNA
<213> Agkistrodon contortrix
<220>
<223> Native profibrolase of Agkistrodon Contortrix
<400> 5

```
atgagatttc cttcaatttt tactgctgtt ttattcgcag catcctccgc attagctgct 60
```

```
ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt 120
tactcagatt tagaagggga tttcgatgtt gctgttttgc cattttccaa cagcacaaat 180
aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240
tctctcgaga aaagagaggc tgaagcttct tctattatct tggaatctgg taacgttaac 300
gattacgaag ttgtttatcc aagaaaggtc actccagttc ctaggggtgc tgttcaacca 360
aagtacgaag atgccatgca atacgaattc aaggttaaca gtgaaccagt tgtcttgcac 420
ttggaaaaaa acaaaggttt gttctctgaa gattactctg aaactcatta ctccccagat 480
ggtagagaaa ttactactta cccattgggt gaagatcact gttactacca tggtagaatc 540
gaaaacgatg ctgactccac tgcttctatc tctgcttgta acggtttgaa gggtcatttc 600
aagttgcaag gtgaaatgta cttgattgaa ccattggaat tgtccgactc tgaagcccat 660
gctgtctaca agtacgaaaa cgtcgaaaag gaagatgaag ccccaaagat gtgtggtgtt 720
acccaaaact gggaatcata tgaaccaatc aagaaggcct tccaattaaa cttgactaag 780
agacaacaaa gattcccaca aagatacgta cagctggtta tcgttgctga ccaccgtatg 840
aacactaaat acaacggtga ctctgacaaa atccgtcaat gggtgcacca aatcgtcaac 900
accattaacg aaatctacag accactgaac atccaattca ctttggttgg tttggaaatc 960
tggtccaacc aagatttgat caccgttact tctgtatccc acgacactct ggcatccttc 1020
ggtaactggc gtgaaaccga cctgctgcgt cgccaacgtc atgataacgc tcaactgctg 1080
accgctatcg acttcgacgg tgatactgtt ggtctggctt acgttggtgg catgtgtcaa 1140
ctgaaacatt ctactggtgt tatccaggac cactccgcta ttaacctgct ggttgctctg 1200
accatggcac acgaactggg tcataacctg ggtatgaacc acgatggcaa ccagtgtcac 1260
tgcggtgcaa actcctgtgt tatggctgct atgctgtccg atcaaccatc caaactgttc 1320
tccgactgct ctaagaaaga ctaccagacc ttcctgaccg ttaacaaccc gcagtgtatc 1380
ctgaacaaac cg                                                     1392
```

<210> 6
<211> 1386
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: proNAT (analog of profibrolase of Agkistrodon Contortrix
<400> 6

```
atgagatttc cttcaatttt tactgctgtt ttattcgcag catcctccgc attagctgct 60
ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt 120
tactcagatt tagaagggga tttcgatgtt gctgttttgc cattttccaa cagcacaaat 180
aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240
tctctcgaga aaagagaggc tgaagcttct tctattatct tggaatctgg taacgttaac 300
gattacgaag ttgtttatcc aagaaaggtc actccagttc ctaggggtgc tgttcaacca 360
aagtacgaag atgccatgca atacgaattc aaggttaaca gtgaaccagt tgtcttgcac 420
ttggaaaaaa acaaaggttt gttctctgaa gattactctg aaactcatta ctccccagat 480
ggtagagaaa ttactactta cccattgggt gaagatcact gttactacca tggtagaatc 540
gaaaacgatg ctgactccac tgcttctatc tctgcttgta acggtttgaa gggtcatttc 600
aagttgcaag gtgaaatgta cttgattgaa ccattggaat tgtccgactc tgaagcccat 660
gctgtctaca agtacgaaaa cgtcgaaaag gaagatgaag ccccaaagat gtgtggtgtt 720
acccaaaact gggaatcata tgaaccaatc aagaaggcct tccaattaaa cttgactaag 780
agatctttcc cacaaagata cgtacagctg gttatcgttg ctgaccaccg tatgaacact 840
aaatacaacg gtgactctga caaaatccgt caatgggtgc accaaatcgt caacaccatt 900
aacgaaatct acagaccact gaacatccaa ttcactttgg ttggtttgga aatctggtcc 960
aaccaagatt tgatcaccgt tacttctgta tcccacgaca ctctggcatc cttcggtaac 1020
tggcgtgaaa ccgacctgct gcgtcgccaa cgtcatgata acgctcaact gctgaccgct 1080
atcgacttcg acggtgatac tgttggtctg gcttacgttg gtggcatgtg tcaactgaaa 1140
cattctactg gtgttatcca ggaccactcc gctattaacc tgctggttgc tctgaccatg 1200
gcacacgaac tgggtcataa cctgggtatg aaccacgatg gcaaccagtg tcactgcggt 1260
```

```
gcaaactcct gtgttatggc tgctatgctg tccgatcaac catccaaact gttctccgac 1320
tgctctaaga aagactacca gaccttcctg accgttaaca acccgcagtg tatcctgaac 1380
aaaccg                                                            1386
```

Claims

1. A pharmaceutical composition comprising a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), a zinc stabilizer and, optionally, a bulking agent, in a pharmaceutically-acceptable buffer.

2. The pharmaceutical composition of Claim 1 wherein the zinc stabilizer is a water soluble zinc salt selected from the group consisting of zinc sulfate, zinc acetate and zinc chloride.

3. The pharmaceutical composition of Claim 1 wherein the buffer is citric acid or a water soluble citric acid salt.

4. The pharmaceutical composition of Claim 1 wherein the bulking agent is mannitol.

5. The pharmaceutical composition of Claim 1 that has a pH in the range of 6.5 to 8.5.

6. The pharmaceutical composition of Claim 1 that is in the form of a frozen liquid.

7. The pharmaceutical composition of Claim 6 that optionally contains a water soluble calcium salt.

8. The pharmaceutical composition of Claim 7 in which the water soluble calcium salt is selected from the group consisting of calcium acetate, calcium sulfate and calcium chloride.

9. The pharmaceutical composition of Claim 1 that is lyophilized.

10. An aqueous pharmaceutical composition of Claim 1,
    wherein the metalloproteinase fibrinolytic agent is present in an amount from 0.1 to 50 mg/ml;
    wherein the zinc stabilizer comprises from 0.08 to 0.12 mM of zinc sulfate;
    wherein the pharmaceutically-acceptable buffer comprises from 0.008 mM to 0.012 mM of calcium acetate, and from 95 to 110 mM of citric acid or sodium citrate; and
    wherein the pH of said composition is 7.4.

11. The pharmaceutical composition according to Claim 10,
    wherein the metalloproteinase is present in an amount of 10 mg/ml;
    wherein said citric acid is present at a concentration of 100 mM;
    wherein said calcium acetate is present at a concentration of 0.01 mM; and
    wherein said zinc sulfate is present at a concentration of 0.1 mM.

12. An aqueous pharmaceutical composition of Claim 1,
    wherein the metalloproteinase fibrinolytic agent is present in an amount from 0.1 to 50 mg/ml;
    wherein the zinc stabilizer comprises from 0.08 to 0.12 mM of zinc acetate;
    wherein the pharmaceutically-acceptable buffer comprises 18 to 22 mM of citric acid or sodium citrate, and 0.02 to 0.06 mM of Tris;
    wherein the optional bulking agent is present and said bulking agent comprises from 3 to 6 percent (w/v) of mannitol;
    wherein there is present a further stabilizer comprising from 0.008 to 0.012 percent (w/v) of surfactant; and
    wherein the pH of said composition is 8.0.

13. An aqueous pharmaceutical composition of Claim 1,
    wherein the metalloproteinase fibrinolytic agent is present in an amount from 0.1 to 50 mg/ml;

wherein the zinc stabilizer comprises from 0.08 to 0.12 mM of zinc sulfate;
wherein the pharmaceutically acceptable buffer comprises from 18 to 22 mM of citric acid or sodium citrate, and 3 to 6 mM of Tris;
wherein the optional bulking agent is present and said bulking agent comprises from 3 to 6 percent (w/v) of mannitol;
wherein there is present a further stabilizer comprising from 0.008 to 0.012 percent (w/v) of surfactant, and optionally 0.1 to 0.5 percent (w/v) of sucrose; and
wherein the pH of said composition is 8.0.

14. The pharmaceutical composition according to Claim 13,
wherein the metalloproteinase is present at a concentration of 12 mg/ml;
wherein said Tris is present at a concentration of 5 mM;
wherein said citric acid is present at a concentration of 20 mM;
wherein said mannitol is present at a concentration of 5 percent (w/v);
wherein said sucrose is present at a concentration of 0.5 percent (w/v);
wherein said surfactant is present at a concentration of 0.01 percent (w/v);
wherein said zinc sulfate is present at a concentration of 0.1 mM; and
wherein the pH of said composition is 8.0.

15. The pharmaceutical composition according to any one of Claims 1 to 14, wherein the metalloproteinase is NAT having the amino acid sequence of SEQ ID NO:1.

16. The pharmaceutical composition according to any one of Claims 1 to 14, wherein the metalloproteinase is fibrolase having the amino acid sequence of SEQ ID NO:3.

17. A method for preparing a lyophilized composition, comprising the steps of:

(a) forming a mixture of a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), a zinc salt, a bulking agent, a stabilizing disaccharide and a surfactant in a buffer, and
(b) lyophilizing the mixture from step (a).

18. The method of Claim 17, in which the pH of said composition is adjusted to between 7.8 and 8.2 prior to lyophilization.

19. The method of Claim 17, comprising the steps of:

(a) adjusting the pH of a solution containing the zinc salt, bulking agent, and stabilizing disaccharide to a pH between 7.6 and 8.2,
(b) buffer exchanging the mixture containing the metalloproteinase into the solution of step (a), and then adding an effective amount of the surfactant, and
(c) lyophilizing the mixture of step (b).

20. The method of any one of Claims 17 to 19 in which the metalloproteinase is NAT having the amino acid sequence of SEQ ID NO: 1.

21. The method of any one of Claims 17 to 19 in which the metalloproteinase is fibrolase having the amino acid sequence of SEQ ID NO:3.

22. A lyophilized pharmaceutical composition obtainable by the method of any one of Claims 17 to 21.

23. The composition according to any one of Claims 1 to 16 for blood clot lysis treatment.

24. Use of the composition according to any one of Claims 1 to 16 for the manufacture of a medicament for blood clot lysis treatment.

25. A kit for preparing an aqueous pharmaceutical composition comprising a first container having a lyophilized composition of a zinc stabilizer and a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase

and novel acting thrombolytic (NAT), and a second container having a physiologically acceptable solvent for the lyophilized composition.

26. The kit of Claim 25, wherein the metalloproteinase fibrinolytic agent is NAT having the amino acid sequence of SEQ ID NO: 1.

27. The kit of Claim 25, wherein the metalloproteinase fibrinolytic agent is fibrolase having the amino acid sequence of SEQ ID NO: 3.

28. An *in vitro* method of lysing a fibrin clot, the method comprising contacting the fibrin clot with a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and novel acting thrombolytic (NAT), a zinc stabilizer and, optionally, a bulking agent, in a pharmaceutically-acceptable buffer.

29. The method of Claim 28, wherein the metalloproteinase fibrinolytic agent is NAT having the amino acid sequence of SEQ ID NO: 1.

30. The method of Claim 28, wherein the metalloproteinase fibrinolytic agent is fibrolase having the amino acid sequence of SEQ ID NO: 3.

31. A method comprising the step of reconstituting the lyophilized, pharmaceutical composition of Claim 9 or Claim 22.

32. A composition obtainable by the method of Claim 31 for use in blood clot lysis treatment

33. Use of the method of Claim 31 for the manufacture of a medicament for blood clot lysis treatment.

Revendications

1. Composition pharmaceutique comprenant un agent fibrinolytique de métalloprotéinase choisi à partir du groupe composé de fibrolase et d'un nouvel acteur thrombolytique (NAT), un stabilisant de zinc et, éventuellement, un diluant, dans un tampon pharmaceutiquement acceptable.

2. Composition pharmaceutique selon la revendication 1, dans laquelle le stabilisant de zinc est un sel de zinc soluble dans l'eau choisi à partir du groupe composé de sulfate de zinc, d'acétate de zinc et de chlorure de zinc.

3. Composition pharmaceutique selon la revendication 1, dans laquelle le tampon est de l'acide citrique ou un sel d'acide citrique soluble dans l'eau.

4. Composition pharmaceutique selon la revendication 1, dans laquelle le diluant est le mannitol.

5. Composition pharmaceutique selon la revendication 1, qui présente un pH dans la plage de 6,5 à 8,5.

6. Composition pharmaceutique selon la revendication 1, qui est sous la forme d'un liquide congelé.

7. Composition pharmaceutique selon la revendication 6, qui contient éventuellement un sel de calcium soluble dans l'eau.

8. Composition pharmaceutique selon la revendication 7, dans laquelle le sel de calcium soluble dans l'eau est choisi à partir du groupé composé d'acétate de calcium, de sulfate de calcium et de chlorure de calcium.

9. Composition pharmaceutique selon la revendication 1, qui est lyophilisée.

10. Composition pharmaceutique aqueuse de la revendication 1, dans laquelle l'agent fibrinolytique de métalloprotéinase est présent dans une quantité de 0,1 à 50 mg/ml ;
dans laquelle le stabilisant de zinc comprend de 0,08 à 0,12 mM de sulfate de zinc ;
dans laquelle le tampon pharmaceutiquement acceptable comprend de 0,008 mM à 0,012 mM d'acétate de calcium, et de 95 à 110 mM d'acide citrique ou de citrate de sodium ; et
dans laquelle le pH de ladite composition est 7,4.

11. Composition pharmaceutique selon la revendication 10,
dans laquelle la métalloprotéinase est présente dans une quantité de 10 mg/ml ;
dans laquelle ledit acide citrique est présent à une concentration de 100 mM ;
dans laquelle ledit acétate de calcium est présent à une concentration de 0,01 mM ; et
dans laquelle ledit sulfate de zinc est présent à une concentration de 0,1 mM.

12. Composition pharmaceutique aqueuse de la revendication 1,
dans laquelle l'agent fibrinolytique de métalloprotéinase est présent dans une quantité de 0,1 à 50 mg/ml ;
dans laquelle le stabilisant de zinc comprend de 0,08 à 0,12 mM d'acétate de zinc ;
dans laquelle le tampon pharmaceutiquement acceptable comprend de 18 à 22 mM d'acide citrique ou de citrate de sodium, et de 0,02 à 0,06 mM de Tris ;
dans laquelle le diluant éventuel est présent et ledit diluant comprend de 3 à 6% (p/v) de mannitol ;
dans laquelle il est présent un autre stabilisant comprenant de 0,008 à 0,012% (p/v) de tensioactif ; et
dans laquelle le pH de ladite composition est 8,0.

13. Composition pharmaceutique aqueuse de la revendication 1,
dans laquelle l'agent fibrinolytique de métalloprotéinase est présent dans une quantité de 0,1 à 50 mg/ml ;
dans laquelle le stabilisant de zinc comprend de 0,08 à 0,12 mM de sulfate de zinc ;
dans laquelle le tampon pharmaceutiquement acceptable comprend de 18 à 22 mM d'acide citrique ou de citrate de sodium, et de 3 à 6 mM de Tris ;
dans laquelle le diluant éventuel est présent et ledit diluant comprend de 3 à 6% (p/v) de mannitol ;
dans laquelle il est présent un autre stabilisant comprenant de 0,008 à 0,012% (p/v) de tensioactif, et éventuellement de 0,1 à 0,5% (p/v) de saccharose ; et
dans laquelle le pH de ladite composition est 8,0.

14. Composition pharmaceutique selon la revendication 13,
dans laquelle la métalloprotéinase est présente à une concentration de 12 mg/ml ;
dans laquelle ledit Tris est présent à une concentration de 5 mM ;
dans laquelle ledit acide citrique est présent à une concentration de 20 mM ;
dans laquelle ledit mannitol est présent à une concentration de 5 % (p/v) ;
dans laquelle ledit saccharose est présent à une concentration de 0,5% (p/v) ;
dans laquelle ledit tensioactif est présent à une concentration de 0,01 % (p/v) ;
dans laquelle ledit sulfate de zinc est présent à une concentration de 0,1 mM ; et
dans laquelle le pH de ladite solution est 8,0.

15. Composition pharmaceutique selon une quelconque des revendications 1 à 14,
dans laquelle la métalloprotéinase est le NAT ayant la séquence d'acides aminés de la SEQ ID N° 1 ;

16. Composition pharmaceutique selon une quelconque des revendications 1 à 14,
dans laquelle la métalloprotéinase est la fibrolase ayant la séquence d'acides aminés de la SEQ ID N° 3.

17. Procédé pour préparer une composition lyophilisée, comprenant les étapes de :

(a) former un mélange d'un agent fibrinolytique de métalloprotéinase choisi à partir du groupe composé de fibrolase et d'un nouvel acteur thrombolytique (NAT), un sel de zinc, un diluant, un disaccharide stabilisant et un tensioactif dans un tampon, et
(b) lyophiliser le mélange de l'étape (a).

18. Procédé selon la revendication 17, dans lequel le pH de ladite composition est réglé entre 7,8 et 8,2 avant lyophilisation.

19. Procédé selon la revendication 17, comprenant les étapes de :

(a) régler le pH d'une solution contenant le set de zinc, le diluant et le disaccharide stabilisant à un pH entre 7,6 et 8,2 ;
(b) échanger par tampon le mélange contenant la métalloprotéinase dans la solution de l'étape (a), et ensuite ajouter une quantité efficace du tensioactif, et
(c) lyophiliser le mélange de l'étape (b).

20. Procédé selon une quelconque des revendications 17 à 19, dans lequel la métalloprotéinase est le NAT ayant la séquence d'acides aminés de la SEQ ID N° 1.

21. Procédé selon une quelconque des revendications 17 à 19, dans lequel la métalloprotéinase est la fibrolase ayant la séquence d'acides aminés de la SEQ ID N° 3.

22. Composition pharmaceutique lyophilisée pouvant être obtenue par le procédé de l'une quelconque des revendications 17 à 21.

23. Composition selon une quelconque des revendications 1 à 16 pour le traitement par lyse de caillots sanguins.

24. Utilisation de la composition selon une quelconque des revendications 1 à 16 pour la fabrication d'un médicament pour le traitement par lyse de caillots sanguins.

25. Kit pour préparer une composition pharmaceutique aqueuse comprenant un premier récipient ayant une composition lyophilisée d'un stabilisant de zinc et d'un agent fibrinolytique de métalloprotéinase choisi à partir du groupe composé dé fibrolase et d'un nouvel acteur thrombolytique (NAT), et un second récipient ayant un solvant physiologiquement acceptable pour la composition lyophilisée.

26. Kit selon la revendication 25, dans lequel l'agent fibrinolytique de métalloprotéinase est le NAT ayant la séquence d'acides aminés de la SEQ ID N° 1.

27. Kit selon la revendication 25, dans lequel l'agent fibrinolytique de métalloprotéinase est la fibrolase ayant la séquence d'acides aminés de la SEQ ID N° 3.

28. Procédé in vitro de lyse d'un caillot sanguin, le procédé consistant à mettre en contact le caillot de fibrine avec un agent fibrinolytique de métalloprotéinase choisi à partir du groupe composé de fibrolase et d'un nouvel acteur thrombolytique (NAT), un stabilisant de zinc et, éventuellement, un diluant, dans un tampon pharmaceutiquement acceptable.

29. Procédé selon la revendication 28, dans lequel l'agent fibrinolytique de métalloprotéiriase est un NAT ayant la séquence d'acides aminés de la SEQ ID N° 1.

30. Procédé selon la revendication 28, dans lequel l'agent fibrinolytique de métalloprotéinase est la fibrolase ayant la séquence d'acides aminés de la SEQ ID N° 3.

31. Procédé comprenant l'étape de reconstituer la composition pharmaceutique lyophilisée de la revendication 9 ou de la revendication 22.

32. Composition pouvant être obtenue par le procédé de la revendication 31 pour l'utilisation dans le traitement par lyse de caillots sanguins.

33. Utilisation du procédé de la revendication 31 pour la fabrication d'un médicament pour le traitement par lyse de caillots sanguins.

Patentansprüche

1. Eine pharmazeutische Zusammensetzung, umfassend ein fibrinolytisches Metalloproteinase-Mittel, ausgewählt aus der Gruppe, bestehend aus Fibrolase und neuem wirksamem Thrombolytikum (NAT), einen Zinkstabilisator und, fakultativ, einen Füllstoff, in einem pharmazeutisch akzeptablen Puffer.

2. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Zinkstabilisator ein wasserlösliches Zinksalz ist, ausgewählt aus der Gruppe, bestehend aus Zinksulfat, Zinkacetat und Zinkchlorid.

3. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Puffer Zitronensäure oder ein wasserlösliches Zitronensäuresalz ist.

4. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Füllstoff Mannitol ist.

5. Pharmazeutische Zusammensetzung nach Anspruch 1, die einen pH im Bereich von 6,5 bis 8,5 hat.

6. Pharmazeutische Zusammensetzung nach Anspruch 1, die in der Form einer gefrorenen Flüssigkeit ist.

7. Pharmazeutische Zusammensetzung nach Anspruch 6, die fakultativ ein wasserlösliches Calciumsalz enthält.

8. Pharmazeutische Zusammensetzung nach Anspruch 7, in der das wasserlösliche Calciumsalz ausgewählt ist aus der Gruppe, bestehend aus Calciumacetat, Calciumsulfat und Calciumchlorid.

9. Pharmazeutische Zusammensetzung nach Anspruch 1, die lyophilisiert ist.

10. Wäßrige pharmazeutische Zusammensetzung nach Anspruch 1,
wobei das fibrinolytische Metalloproteinase-Mittel in einer Menge von 0,1 bis 50 mg/ml vorliegt;
wobei der Zinkstabilisator 0,08 bis 0,12 mM Zinksulfat umfaßt;
wobei der pharmazeutisch akzeptable Puffer 0,008 mM bis 0,012 mM Calciumacetat und 95 bis 110 mM Zitronensäure oder Natriumcitrat umfaßt; und
wobei der pH besagter Zusammensetzung 7,4 ist.

11. Pharmazeutische Zusammensetzung nach Anspruch 10,
wobei die Metalloproteinase in einer Menge von 10 mg/ml vorliegt;
wobei besagte Zitronensäure in einer Konzentration von 100 mM vorliegt;
wobei besagtes Calciumacetat in einer Konzentration von 0,01 mM vorliegt; und
wobei besagtes Zinksulfat in einer Konzentration von 0,1 mM vorliegt.

12. Wäßrige pharmazeutische Zusammensetzung nach Anspruch 1,
wobei das fibrinolytische Metalloproteinase-Mittel in einer Menge von 0,1 bis 50 mg/ml vorliegt;
wobei der Zinkstabilisator 0,08 bis 0,12 mM Zinkacetat umfaßt;
wobei der pharmazeutisch akzeptable Puffer 18 bis 22 mM Zitronensäure oder Natriumcitrat und 0,02 bis 0,06 mM Tris umfaßt;
wobei das fakultative Füllmittel vorhanden ist und besagtes Füllmittel 3 bis 6 Prozent (Gew./Vol.) Mannitol umfaßt;
wobei ein weiterer Stabilisator vorhanden ist, umfassend 0,008 bis 0,012 Prozent (Gew./Vol.) oberflächenaktives Mittel; und
wobei der pH besagter Zusammensetzung 8,0 ist.

13. Wäßrige pharmazeutische Zusammensetzung nach Anspruch 1,
wobei das fibrinolytische Metalloproteinase-Mittel in einer Menge von 0,1 bis 50 mg/ml vorliegt;
wobei der Zinkstabilisator 0,08 bis 0,12 mM Zinksulfat umfaßt;
wobei der pharmazeutisch akzeptable Puffer 18 bis 22 mM Zitronensäure oder Natriumcitrat und 3 bis 6 mM Tris umfaßt;
wobei das fakultative Füllmittel vorhanden ist und besagtes Füllmittel 3 bis 6 Prozent (Gew./Vol.) Mannitol umfaßt;
wobei ein weiterer Stabilisator vorhanden ist, umfassend 0,008 bis 0,012 Prozent (Gew./Vol.) oberflächenaktives Mittel und, fakultativ, 0,1 bis 0,5 Prozent (Gew./Vol.) Saccharose; und
wobei der pH besagter Zusammensetzung 8,0 ist.

14. Pharmazeutische Zusammensetzung nach Anspruch 13,
wobei die Metalloproteinase in einer Konzentration von 12 mg/ml vorliegt;
wobei besagtes Tris in einer Konzentration von 5 mM vorhanden ist;
wobei besagte Zitronensäure in einer Konzentration von 20 mM vorhanden ist;
wobei besagtes Mannitol in einer Konzentration von 5 Prozent (Gew./Vol.) vorhanden ist;
wobei besagte Saccharose in einer Konzentration von 0,5 Prozent (Gew./Vol.) vorhanden ist;
wobei besagtes oberflächenaktives Mittel in einer Konzentration von 0,01 Prozent (Gew./Vol.) vorhanden ist;
wobei besagtes Zinksulfat in einer Konzentration von 0,1 mM vorhanden ist; und
wobei der pH besagter Zusammensetzung 8,0 ist.

15. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 14, wobei die Metalloproteinase NAT mit der Aminosäuresequenz von SEQ ID NO: 1 ist.

16. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 bis 14, wobei die Metalloproteinase Fibrolase mit der Aminosäuresequenz von SEQ ID NO:3 ist.

17. Ein Verfahren zum Herstellen einer lyophilisierten Zusammensetzung, umfassend die Schritte:

(a) Bilden einer Mischung aus einem fibrinolytischen Metalloproteinase-Mittel, ausgewählt aus der Gruppe, bestehend aus Fibrolase und neuem wirksamem Thrombolytikum (NAT), einem Zinksalz, einem Füllmittel, einem stabilisierenden Disaccharid und einem oberflächenaktiven Mittel in einem Puffer, und
(b) Lyophilisieren der Mischung aus Schritt (a).

18. Verfahren nach Anspruch 17, in dem der pH besagter Zusammensetzung auf zwischen 7,8 und 8,2 vor der Lyophilisierung eingestellt wird.

19. Verfahren nach Anspruch 17, umfassend die Schritte:

(a) Einstellen des pHs einer Lösung, enthaltend das Zinksalz, Füllmittel und stabilisierendes Disaccharid, auf einen pH zwischen 7,6 und 8,2,
(b) Austauschen des Puffers der Mischung, enthaltend die Metalloproteinase, in die Lösung aus Schritt (a) und dann Zugeben einer wirksamen Menge des oberflächenaktiven Mittels, und
(c) Lyophilisieren der Mischung aus Schritt (b).

20. Verfahren nach einem der Ansprüche 17 bis 19, bei dem die Metalloproteinase NAT mit der Aminosäuresequenz von SEQ ID NO:1 ist.

21. Verfahren nach einem der Ansprüche 17 bis 19, bei dem die Metalloproteinase Fibrolase mit der Aminosäuresequenz von SEQ ID NO:3 ist.

22. Eine lyophilisierte pharmazeutische Zusammensetzung, erhältlich durch das Verfahren nach einem der Ansprüche 17 bis 21.

23. Zusammensetzung nach einem der Ansprüche 1 bis 16 zur Blutgerinnsel-Lyse-Behandlung.

24. Verwendung der Zusammensetzung nach einem der Ansprüche 1 bis 16 zur Herstellung eines Medikaments zur Blutgerinnsel-Lyse-Behandlung.

25. Ein Kit zum Herstellen einer wäßrigen pharmazeutischen Zusammensetzung, umfassend einen ersten Behälter mit einer lyophilisierten Zusammensetzung aus einem Zinkstabilisator und einem fibrinolytischen Metalloproteinase-Mittel, ausgewählt aus der Gruppe, bestehend aus Fibrolase und neuem wirksamem Thrombolytikum (NAT), und einen zweiten Behälter mit einem physiologisch akzeptablen Lösungsmittel für die lyophilisierte Zusammensetzung.

26. Kit nach Anspruch 25, wobei das fibrinolytische Metalloproteinase-Mittel NAT mit der Aminosäuresequenz von SEQ ID NO:1 ist.

27. Kit nach Anspruch 25, wobei das fibrinolytische Metalloproteinase-Mittel Fibrolase mit der Aminosäuresequenz von SEQ ID NO:3 ist.

28. Ein *in-vitro* Verfahren zum Lysieren eines Fibringerinnsels, wobei das Verfahren umfaßt: In-Kontakt-Bringen des Fibrin-Gerinnsels mit einem fibrinolytischen Metalloproteinase-Mittel, ausgewählt aus der Gruppe, bestehend aus Fibrolase und neuem wirksamem Thrombolytikum (NAT), einem Zinkstabilisator und, fakultativ, einem Füllmittel, in einem pharmazeutisch akzeptablen Puffer.

29. Verfahren nach Anspruch 28, wobei das fibrinolytische Metalloproteinase-Mittel NAT mit der Aminosäuresequenz von SEQ ID NO:1 ist.

30. Verfahren nach Anspruch 28, wobei das fibrinolytische Metalloproteinase-Mittel Fibrolase mit der Aminosäuresequenz von SEQ ID NO:3 ist.

31. Ein Verfahren, umfassend den Schritt des Rekonstituierens der lyophilisierten pharmazeutischen Zusammensetzung nach Anspruch 9 oder Anspruch 22.

32. Zusammensetzung, erhältlich durch das Verfahren nach Anspruch 31 zur Verwendung bei der Blutgerinnsel-Lyse-Behandlung.

33. Verwendung des Verfahrens nach Anspruch 31 zur Herstellung eines Medikaments zur Blutgerinnsel-Lyse-Behandlung.

REGISTER ENTRY FOR EP1220685

European Application No EP00967197.5 filing date 29.09.2000

Priority claimed:
01.10.1999 in United States of America - doc: 411335

PCT EUROPEAN PHASE
PCT Application PCT/US2000/027022 Publication No WO2001/024817 on 12.04.2001

Designated States AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Title PHARMACEUTICAL COMPOSITIONS OF FIBRINOLYTIC AGENT

Applicant/Proprietor
AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States of America [ADP No. 50901446003]

Inventors
BRENT S. KENDRICK, 575 W. Linden Street, Louisville, CO 80027, United States of America [ADP No. 70613252001]

BRIAN PETERSON, 207 Rustling Heights, Simi Valley, CA 93065, United States of America [ADP No. 70613260001]

Classified to
A61K A61P

Address for Service
AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States of America [ADP No. 50901446003]

EPO Representative
KATE RICHARDSON, Forrester & Boehmert, Pettenkoferstrasse 20-22, 80336 München, Federal Republic of Germany [ADP No. 68192707001]

Publication No EP1220685 dated 10.07.2002
Publication in English

Examination requested 25.03.2002

Patent Granted with effect from 31.03.2004 (Section 25(1)) with title
PHARMACEUTICAL COMPOSITIONS OF FIBRINOLYTIC AGENT

27.02.2004 EPO: Search report published on 18.10.2001
Entry Type 25.11 Staff ID. RD06 Auth ID. EPT

13.05.2004 Notification of change of Address For Service name and address of
AMGEN INC., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States of America [ADP No. 50901446003]
to
FORRESTER KETLEY & CO, Forrester House, 52 Bounds Green Road, LONDON, N11 2EY, United Kingdom [ADP No. 00000133001]
dated 10.05.2004. Official evidence filed on EP Reg Main
Entry Type 7.1 Staff ID. MJON Auth ID. F51

**** END OF REGISTER ENTRY ****

RENEWAL DETAILS

PUBLICATION NUMBER EP1220685

PROPRIETOR(S)

Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States of America

DATE FILED 29.09.2000

DATE GRANTED 31.03.2004

DATE NEXT RENEWAL DUE 29.09.2004

DATE NOT IN FORCE

DATE OF LAST RENEWAL

YEAR OF LAST RENEWAL 00

STATUS PATENT IN FORCE

**** END OF REPORT ****